RPTX

Repare Therapeutics Inc. | Cotação de Ações

Última atualização24/12/2024, 15:00:00

PreçoUS$ 1,35

Variação (dia)-- (0.00%)▼

Min. 52 SemanasUS$ 1,23

Máx. 52 SemanasUS$ 8,49

Capitalização de mercado--

Endereço: 7171 Frederick-Banting, Building 2, Montreal, QC, H4S 1Z9

Telefone: 857 412 7018

Funcionários: 179

Repare Therapeutics Inc.RPTX

US$ 1,35

24/12/2024 15:00:00

1D 7D 1M 3M 1A Tudo

Visão geral da empresa

Preço atualUS$ 1,35

Valor de mercado--

AberturaUS$ 1,46

Preço máximoUS$ 1,36

Preço mínimoUS$ 1,29

VolumeUS$ 232 mil

Fechamento anteriorUS$ 1,35

Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing Lunresertib (RP-6306), a PKMYT1 Inhibitor, which is under Phase I/Ib clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; RP-1664, an oral PLK4 inhibitor, under Phase 1 clinical trial designed to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, a polymerase theta adenosinetriphosphatase (ATPase) inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company has license and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; New York University; Foundation Medicine, Inc. for the provision of prospective genomic profiling of lunresertib alone or in combinations in genomically-defined patient populations; cooperative research and development agreement with US National Cancer Institute to advance the development of Camonsertib; and Ono Pharmaceutical Co., as well as a clinical study and collaboration agreement with Debiopharm to explore the synthetic lethal combination of PKMYT1 and WEE1 inhibition in cancer. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montreal, Canada.

Ações relacionadas

Accolade, Inc.

ACCD ▼0.05% | US$ 3,40

Nurix Therapeutics, Inc.

NRIX ▼0.41% | US$ 19,57

908 Devices Inc.

MASS ▲0.02% | US$ 1,92

Relay Therapeutics, Inc.

RLAY ▼0.11% | US$ 4,23

ORIC Pharmaceuticals, Inc.

ORIC ▼0.14% | US$ 8,19

Conheça os Planos e Preços personalizados para acessar recursos exclusivos

Explore nossos Planos e Preços para obter acesso a recursos exclusivos, atendendo às suas necessidades específicas. Oferecemos opções flexíveis para investidores de todos os níveis, garantindo que você tenha as ferramentas certas para otimizar sua estratégia de investimento.

Fique por dentro das últimas notícias do mundo financeiro em nosso Blog

Mantenha-se atualizado com as últimas notícias financeiras em nosso Blog. Publicamos artigos informativos e análises de especialistas para fornecer insights valiosos sobre o cenário financeiro em constante evolução.

Assine nossa newsletter para receber atualizações gratuitas por e-mail

Mantenha-se informado assinando nossa newsletter. Receba atualizações gratuitas por e-mail, incluindo rendimentos, novidades do mercado e insights valiosos. Estamos comprometidos em fornecer informações relevantes diretamente à sua caixa de entrada.